ALung completes pilot study of Hemolung RAS in COPD patients ALung Systems.

These patients that go on to end up being mechanically ventilated often have a very poor prognosis with survival ranging from 31 percent to 76 percent, said Dr. Nausherwan Burki, Professor of Medicine at the University of Connecticut Health Middle and ALung’s Medical Director. The power of the Hemolung RAS to greatly help patients with serious severe exacerbation of COPD prevent intubation and invasive mechanical ventilation fills an important, unmet clinical need. We are pleased to have finished our pilot research of the Hemolung RAS also to become progressing towards obtainment of the CE mark, said Peter DeComo, ALung’s Chairman and CEO. There can be tremendous scientific enthusiasm for the Hemolung RAS, and we’re looking towards introducing the product to crucial reference centers throughout European countries in the near future.Product revenue for the entire year ended December 31, 2012 was $266.1 million and service and other revenue was $29.5 million. This compares to product revenue of $241.3 million and service and other revenue of $26.2 million in 2011. Product revenue for 2012 included Affymetrix core consumable revenue of $210.7 million, device revenue of $18.4 million and revenue from eBioscience of $37.0 million. Product income for 2011 included Affymetrix core consumable revenue of $225.0 million and instrument revenue of $16.3 million.